MLXIPL and hepatocellular carcinoma: In conclusion, our study proposes that targeting ChREBP activity may serve as an anti-neoplastic strategy and as a promising approach to counteract resistance against systemic therapy during HCC treatment (Supplementary Fig. 17c).